VCAM1 Antikörper (Biotin)

Produktnummer ABIN2192132

Produktdetails anti-VCAM1 Antikörper (Biotin)

Target: VCAM1 (Vascular Cell Adhesion Molecule 1 (VCAM1))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser VCAM1 Antikörper ist konjugiert mit Biotin

Applikation: Flow Cytometry (FACS), Immunoprecipitation (IP), Functional Studies (Func)

Sterilität: 0.2 μm filtered

Klon: 1G11B1

Anwendungsinformationen

Applikationshinweise: For immunohistochemistry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. Positive Activated endothelial cells control

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: PBS, containing 0.02 % sodium azide and 0.1 % bovine serum albumin.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C

Informationen zur Lagerung: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.

Referenzen für anti-VCAM1 Antikörper (Biotin) (ABIN2192132)

Wijbrandts, Dijkgraaf, Kraan, Vinkenoog, Smeets, Dinant, Vos, Lems, Wolbink, Sijpkens, Dijkmans, Tak: "The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium." in: Annals of the rheumatic diseases, Vol. 67, Issue 8, pp. 1139-44, (2008) (PubMed).

Dienst, Grunow, Unruh, Rabausch, Nör, Fries, Gottstein: "Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins." in: Journal of the National Cancer Institute, Vol. 97, Issue 10, pp. 733-47, (2005) (PubMed).

Van der Vieren, Crowe, Hoekstra, Vazeux, Hoffman, Grayson, Bochner, Gallatin, Staunton: "The leukocyte integrin alpha D beta 2 binds VCAM-1: evidence for a binding interface between I domain and VCAM-1." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 163, Issue 4, pp. 1984-90, (1999) (PubMed).

Thornhill, Wellicome, Mahiouz, Lanchbury, Kyan-Aung, Haskard et al.: "Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and ..." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 146, Issue 2, pp. 592-8, (1991) (PubMed).

Details zu VCAM1

Target: VCAM1 (Vascular Cell Adhesion Molecule 1 (VCAM1))

Andere Bezeichnung: Vcam-1 CD106 (VCAM1 Produkte)

Synonyme: CD106 antikoerper, INCAM-100 antikoerper, Vcam-1 antikoerper, VCAM1B antikoerper, fi76d06 antikoerper, wu:fi76d06 antikoerper, zgc:158875 antikoerper, VCAM1 antikoerper, vascular cell adhesion molecule 1 antikoerper, vascular cell adhesion molecule 1b antikoerper, VCAM1 antikoerper, Vcam1 antikoerper, vcam1b antikoerper, VCAM-1 antikoerper

Hintergrund: The monoclonal antibody 1G11B1 recognizes vascular cell adhesion molecule-1 (VCAM-1). VCAM-1 is a member of the immunoglobulin superfamily of adhesion molecules, which includes ICAMs, PECAM-s and MADCAM, and is involved in leukocyte-endothelial cell interactions. The immunoglobulin superfamily is a type I transmembrane protein characterized by extracellular immunoglobin domains, a transmembrane region and a cytoplasmic tail. They are essential for the development of the embryo and for immune and inflammatory responses. These transmembrane glycoproteins mediate cell interaction with, and adhesion to, other cells and the extracellular matrix. VCAM-1 contains six immunoglobulin domains of the H-type and interacts with VLA-4 expressed on leukocytes. Multiple adhesion molecules play a role in leukocyte recruitment. The process of migration of a leukocyte through the vascular endothelium consists of the following steps: leukocyte- endothelium interaction (first tethering and rolling and than adhesion) and transendothelial migration. VCAM-1 is almost not expressed under physiological conditions. However, under appropriate pro-inflammatory conditions where the endothelium is exposed to inflammatory cytokines such as tumour necrosis factor-α or IL-1b and becomes activated, VCAM-1 gene expression is rapid elevated by the vascular endothelium. There is also a soluble form of VCAM-1 which is angiogenic and chemotactic for endothelial cells. sVCAM-1 is up- regulated in several disease states (eg, myocardial infarction, type 2 diabetes mellitus, primary antiphospholipid syndrome, and rheumatoid arthritis). Aliases CD106, INCAM-100, L1CAM, MGC99561, DKFZp779G2333, Immunogen Full length protein

Pathways: Carbohydrate Homeostasis